Detailed reasons for delay in submission of financials results for the period/year ended March 31, 2025, this is with reference to the communication received dated 20.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences responded to a BSE query dated June 20, 2025 regarding the delayed submission of financial results. The company explained that audited results for FY ended March 31, 2025 were uploaded on time, but due to an inadvertent oversight, the quarterly figures for Q4 ended March 31, 2025 were accidentally left out of the PDF submission. Upon realising the omission (and after BSE's communication), the company promptly uploaded the complete and corrected set of results on June 12, 2025. The company clarified this was not a delay per se but an unintentional omission, and stated it has strengthened its internal review controls to prevent recurrence.
This is a procedural compliance matter with no direct impact on business operations or financials. It does, however, flag a weakness in disclosure controls which investors should monitor; the timely correction and assurance of strengthened controls should limit any lasting negative perception.